You are here

SMA

Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up

Fierce Pharma

Sun, 06/20/21 - 10:21 pm

spinal muscular atrophy

Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA

Xtalks

Tue, 06/8/21 - 12:19 pm

Zolgensma flatlines, but Spinraza isn’t the beneficiary

EP Vantage

Wed, 04/28/21 - 10:27 am

Biogen Reports New Spinraza Data in SMA

Global Genes

Wed, 04/21/21 - 10:34 am

Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche

Pharmaforum

Thu, 04/15/21 - 10:02 am

Scholar Rock eyes phase 3 after confirming effects of SMA drug

Fierce Biotech

Tue, 04/6/21 - 10:28 am

clinical trials

Years after a major trial setback, Novartis switches gears with SMA drug. This time they're trying it for Huntington's

Endpoints

Wed, 10/21/20 - 11:43 pm

Huntington's disease

Biogen finally culls MS dud opicinumab, adds SMA gene therapy to the garbage heap

Fierce Biotech

Wed, 10/21/20 - 10:58 am

From no drugs to 3: Patients with spinal muscular atrophy now face hard choices

BioPharma Dive

Mon, 10/5/20 - 11:39 pm

spinal muscular atrophy

FDA sets back Novartis plans to expand use of SMA gene therapy

BioPharma Dive

Wed, 09/23/20 - 10:39 am

clinical trials

Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”

BioSpace

Wed, 08/12/20 - 12:14 am

spinal muscular atrophy

clinical trials

FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

Xconomy

Sat, 08/8/20 - 10:56 pm

spinal muscular atrophy

Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients

MedCity News

Tue, 07/21/20 - 10:37 am

clinical trials

spinal muscular atrophy

OptumRx: The 3 drugs that will have the biggest impact on payers, patients in 2020

Beckers Hospital Review

Thu, 06/11/20 - 10:46 pm

PTC Therapeutics

Duchenne Muscular Dystrophy

triple negative breast cancer

Biogen’s Spinraza Shows Sustained Benefit for Pre-Symptomatic SMA Patients

BioSpace

Wed, 06/10/20 - 11:46 pm

clinical trials

New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy

Fierce Pharma

Wed, 05/20/20 - 10:50 am

spinal muscular atrophy

Roche shares SMA data ahead of scrap with Biogen, Novartis

Fierce Biotech

Tue, 04/28/20 - 10:59 am

spinal muscular atrophy

clinical trials

Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst

Fierce Pharma

Wed, 04/8/20 - 11:03 am

FDA delays decision on Roche spinal muscular atrophy drug

Biopharma Dive

Tue, 04/7/20 - 07:14 pm

A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy

Xconomy

Tue, 03/31/20 - 10:49 am

Pages